http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2362111-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C323-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C317-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-64 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 |
| filingDate | 2006-04-06^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-06-28^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_025d9ce268d385222bed800529f6131f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd3b7c2fa6b45a52e9e83b31af3e7d53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24c56d71f0efccc7e91f4830c06b958d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c6ff908638798f0fa5b04929ea07267 |
| publicationDate | 2011-06-28^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2362111-T3 |
| titleOfInvention | NEW INHIBITORS SPECIFIC TO CASPASA-10. |
| abstract | Use of a compound of formula (I): for the preparation of a medicament for the prevention or treatment of retinopathy, in which formula (I): - R1 represents a group of formula: -X- (Y) m, in where: -X- represents an aryl, cycloalkyl, heteroaryl, alkyl or heterocyclyl group; Each of the Y groups, which may be identical or different, independently represents a halogen atom or a group -alkyl, -O-alkyl, -CO-alkyl, -NO2, -O-perhaloalkyl, -S (O) q -alkyl or -perhaloalkyl, or two Y groups which together form an aryl or heteroaryl group fused to the phenyl nucleus to which they are attached; m represents an integer chosen from 0, 1, 2, 3, 4 and 5; - R2 and R3 together form a cycloalkyl or heterocyclyl group optionally substituted with one or more alkyl groups; - R4 represents a group of formula -Z- (alkyl) n-Tp where -Z- represents -O- or a group -S (O) q- or, if n = p = 0, a halogen atom or a group -OH; T represents a cycloalkyl, heterocyclyl, or heteroaryl group; n represents an integer chosen between 0 and 1; p represents an integer chosen between 0 and 1; - i represents an integer greater than or equal to 2; - R5 represents a hydrogen atom or an alkyl group, optionally substituted with one or more cycloalkyl groups; - Each of the R6 groups, which may be identical or different, independently represent a group chosen from an alkyl group, O-alkyl, a halogen atom and a group -CN, -NO2, -COalkyl, -CO2R, -NRR ', -O-perhaloalkyl or -perhaloalkyl; - j represents an integer chosen from 0, 1, 2, 3 and 4; R and R ', which may be identical or different, independently represent a hydrogen atom or an alkyl group; q represents an integer chosen from 0, 1 and 2; and, in addition, tautomeric, enantiomeric, diastereoisomeric and epimeric forms, esters and pharmaceutically acceptable salts. |
| priorityDate | 2005-04-25^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 324 of 324.